Vevo
Nima Alidoust is the CEO and Co-Founder of Vevo Therapeutics, a biotechnology company focused on improving drug discovery using an innovative in vivo drug discovery platform and AI models. Previously, Nima served as the Founding CEO of Good Chemistry Company, a venture that emerged from 1QBit and was acquired for $75 million. Nima's earlier experience includes leadership roles at Rigetti Computing, where responsibilities spanned product management and strategy in quantum computing, and a tenure at McKinsey & Company, providing strategic insights to clients in advanced industries. Nima's academic credentials include a Ph.D. in Computational and Quantum Chemistry from Princeton University, a B.A. in Physics and Classics from Middlebury College, and an International Baccalaureate from Pearson College UWC.
This person is not in any offices
Vevo
1 followers
Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays. Vevo is using Mosaic to build the world’s largest in vivo atlas of how drugs interact with patient cells and training AI models on its data to find novel targets and drugs undetectable by other technologies. Located in San Francisco, CA, Vevo was founded by a team of inventors and thought leaders who have discovered drugs for “undruggable” targets and invented novel methods in genomics, computational biology, and chemistry. Vevo is backed by leading investors at the intersection of life sciences and technology, including General Catalyst, Wing Venture Capital, Mubadala Capital, AIX Ventures, and Camford Capital. Learn more at www.vevo.ai.